A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of HQP1351 in patients with chronic
myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to first- and
second-generation tyrosine kinase inhibitors. The efficacy of HQP1351 is determined by
evaluating the subjects' event free survival (EFS).